de Andrade Tânia Sueli, de Almeida Ana Maria Zimmer, Basano Sergio de Almeida, Takagi Elizabeth Harummyy, Szeszs Maria Walderez, Melhem Marcia S C, Albuquerque Madson, Camargo Juliana de Souza Almeida Aranha, Gambale Walderez, Camargo Luís Marcelo Aranha
Department of Culture Collection, Adolfo Lutz Institute, Secretary of Health, São Paulo, Brazil.
Department of Biological Sciences, Federal University of Rondônia, Rondônia, Brazil.
Med Mycol. 2020 Feb 1;58(2):172-180. doi: 10.1093/mmy/myz034.
Chromoblastomycosis is a chronic subcutaneous disease caused by human contact with melanized fungi occurring mainly in tropical and subtropical zones worldwide. This study assessed 12 patients with chromoblastomycosis from Rondônia, Brazil, Amazon region. In sum, 83.3% were men, 41.6% were from Monte Negro city, median age was 52.9 years, and median time to disease progression was 12.2 years. Lesions were located on the lower limbs (75%), and verruciform was prevalent form (66.6%). After 3 years of treatment with itraconazole, two patients were considered cured. The etiological agents were identified by the molecular sequence of the ribosomal internal transcribed spacer ITS1, 5.8S, and ITS2 region and β-tubulin genes. Eight strains were identified as Fonsecaea pedrosoi, two were F. nubica, and two were Rhinocladiella similis. The antifungal activity of five drugs was evaluated, and the most active drug was terbinafine (range minimal inhibitory concentration [MIC] 0.015-0.12 μg/ml), itraconazole (range MIC 0.03-0.5 μg/ml) and voriconazole (range MIC 0.06-0.5 μg/ml). The highest MIC was 5-fluorocytosine (range MIC 2-32 μg/ml), and amphotericin B (range MIC 0.25-2 μg/ml). In conclusion, the present study expanded the epidemiological disease database and described for the first time F. nubica and R. similis as chromoblastomycosis agents in the Brazilian Amazon region. Our results confirmed the importance of using molecular methods to identify the melanized fungi and stimulate the recognition of the disease in other places where no cases have been reported.
着色芽生菌病是一种慢性皮下疾病,由人类接触主要存在于全球热带和亚热带地区的黑色素真菌引起。本研究评估了来自巴西朗多尼亚州亚马逊地区的12例着色芽生菌病患者。总体而言,83.3%为男性,41.6%来自蒙特内格罗市,中位年龄为52.9岁,疾病进展的中位时间为12.2年。病变位于下肢(75%),疣状是主要形式(66.6%)。接受伊曲康唑治疗3年后,两名患者被认为治愈。通过核糖体内部转录间隔区ITS1、5.8S和ITS2区域以及β-微管蛋白基因的分子序列鉴定病原体。鉴定出8株裴氏着色霉,2株暗黄着色霉,2株相似支孢瓶霉。评估了五种药物的抗真菌活性,活性最强的药物是特比萘芬(最低抑菌浓度[MIC]范围为0.015 - 0.12μg/ml)、伊曲康唑(MIC范围为0.03 - 0.5μg/ml)和伏立康唑(MIC范围为0.06 - 0.5μg/ml)。最高MIC是5-氟胞嘧啶(MIC范围为2 - 32μg/ml),两性霉素B(MIC范围为0.25 - 2μg/ml)。总之,本研究扩展了该疾病的流行病学数据库,并首次将暗黄着色霉和相似支孢瓶霉描述为巴西亚马逊地区着色芽生菌病的病原体。我们的结果证实了使用分子方法鉴定黑色素真菌的重要性,并促使在其他未报告病例的地方认识该疾病。